Fred D'Amato

Fred D'Amato has a wide range of experience in the pharmaceutical and biotech industry. Fred is currently working as the Sr. Director - Clinical Operations Lead at Kura Oncology, Inc. since June 2022. Prior to this role, they were the Director - Clinical Operations Lead at the same company from September 2020 to June 2022.

Before joining Kura Oncology, Inc., Fred worked at Sarepta Therapeutics as the Director - Gene Therapy, Clinical Operations from February 2019 to September 2020. Fred also held the position of Associate Director Clinical Operations at Sarepta Therapeutics from April 2018 to February 2019.

From June 2016 to November 2017, Fred worked as an Associate Director, Clinical Program Support at Shire (which acquired Baxalta in June 2016). Before that, they were the Clinical Program Lead, Clinical Operations at Baxalta US, Inc. from March 2015 to October 2016.

Fred gained experience in clinical study management at Takeda Pharmaceuticals, where they worked as a Senior Clinical Study Manager from May 2014 to February 2015. Fred also worked at Biogen Idec, where they held various roles including Senior Clinical Trial Manager from February 2013 to May 2014, Clinical Trial Manager from February 2009 to February 2013, and Sr. Clinical Trial Coordinator/Acting Clinical Trial Manager from September 2007 to February 2009.

Fred started their career at the Dana-Farber/Harvard Cancer Center at MGH as a Clinical Research Associate II from 2005 to 2007.

Overall, Fred D'Amato has extensive experience and expertise in clinical operations and study management in the pharmaceutical and biotech industry, with a focus on oncology.

Fred D'Amato obtained their BA in Chemistry from Saint Anselm College, between the years 1993 and 1997. Fred then pursued further education and obtained an MS in Pharmacology from Northeastern University, from 2005 to 2007.